Recently, the Shenzhen entry-exit biomedical special goods Joint regulatory mechanism Joint Conference Office publicized on the website of the Shenzhen Development and Reform Commission the 2024 entry-exit biomedical special goods to be identified pilot enterprises (institutions) "white list" and positive items list. After strict material verification, expert review, on-site verification, consultation with departments and joint meeting review and other links, the city's first batch of 13 enterprises and institutions were approved "white list", Shenzhen Cell Valley was successfully selected, including the core raw material of cell therapy virus vector and other approved special goods entry and exit positive items list.
This selection is one of the important achievements of the pilot work plan of the joint supervision mechanism of entry-exit biomedical special goods in Shenzhen. The plan aims to optimize the entry and exit process of biomedical special goods by establishing a joint supervision mechanism, improve the efficiency of customs clearance, while ensuring the effectiveness of biosecurity and supervision. This initiative will not only help enhance the international competitiveness of Shenzhen's biomedical industry, but also provide more and better biomedical products and services for patients at home and abroad.
Looking forward to the future, Shenzhen Cell Valley will rely on the opportunity of being selected in the "white list", continue to increase scientific research investment, research the underlying core technology, and expand more international business at the beginning of 2025 to promote the continuous innovation and breakthrough of new cell therapy technologies.